Evidence map›Paper›PMID 31939490›Full record

ReviewArchives of endocrinology and metabolism

The position of combined medical treatment in acromegaly.

Eva C Coopmans, Sebastiaan W F van Meyel, Aart J van der Lely, Sebastian J C M M Neggers

Open access · diamondAbstract readReview
In one paragraph

Review in Archives of endocrinology and metabolism. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Changes in olfactory function and olfactory bulb after treatment for acromegaly.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2021
    Trial
  2. Current treatment landscape of acromegaly.The Journal of clinical endocrinology and metabolism · 2026
    Review
  3. Acromegaly: diagnostic challenges and individualized treatment.Expert review of endocrinology & metabolism · 2025
    Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Eva C CoopmansDepartment of Medicine, Section Endocrinology, Pituitary Center Rotterdam, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0003-4780-2468
Sebastiaan W F van MeyelDepartment of Medicine, Section Endocrinology, Pituitary Center Rotterdam, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0002-1148-9863
Aart J van der LelyDepartment of Medicine, Section Endocrinology, Pituitary Center Rotterdam, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0002-1059-0126
Sebastian J C M M NeggersDepartment of Medicine, Section Endocrinology, Pituitary Center Rotterdam, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.
Erasmus MC · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advances in combination medical treatment have offer new perspectives for acromegaly patients with persistent disease activity despite receiving the available medical monotherapies. The outcomes of combination medical treatment may reflect both additive and synergistic effects. This review focuses on combination medical treatment and its current position in acromegaly, based on clinical studies evaluating the efficacy and safety of combined medical treatment(s) and our own experiences with combination therapy. Arch Endocrinol Metab. 2019;63(6):646-52.

Indexed as

AcromegalyDopamine AgonistsDrug Therapy, CombinationHuman Growth HormoneHumansQuality of LifeReceptors, SomatostatinReceptors, SomatotropinSomatostatinDopamine AgonistsHuman Growth HormonepasireotidepegvisomantReceptors, SomatostatinReceptors, SomatotropinSomatostatin

Identifiers

PMID31939490
PMCPMC10522231
OpenAlexW2999074795

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.